Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Drug Dosage Regimen: Overview

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

Dosage Regimen: Individualization

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Dosage Regimen: Multiple Oral Dosage

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Dosage Regimen: Fixed Dose

Dosage Regimen: Fixed Dose

Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Intravenous Regular Insulin for Treatment of Hyperkalemia in Overweight Patients.

Pharmacotherapy·2025

Same author

Correction to: Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study.

Journal of thrombosis and thrombolysis·2025

Same author

Comparison of Error Incidence Between Single-Tablet Versus Multiple-Tablet INSTI-Based Regimens in the Inpatient Setting.

The Annals of pharmacotherapy·2025

Same author

Apixaban versus warfarin for treatment of venous thromboembolism in patients with severe renal impairment: a multicenter study.

Journal of thrombosis and thrombolysis·2025

Same author

Doxycycline Versus Vancomycin for the Treatment of Methicillin-Resistant <i>Staphylococcus Aureus-Associated</i> Acute Pulmonary Exacerbations in People With Cystic Fibrosis.

The Annals of pharmacotherapy·2025

Same author

Evaluation of an inpatient automatic dose reduction protocol for concentrated insulin glargine upon therapeutic interchange to insulin detemir on hypoglycemia rates.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·2024

Search research articles

Related Experiment Video

Updated: Feb 7, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

HIV Clinical Updates: New Single-Tablet Regimens.

Jamielynn C Sebaaly¹, Denise Kelley²

¹1 Wingate University School of Pharmacy, Wingate, NC, USA.

The Annals of Pharmacotherapy

|August 4, 2018

Summary

New single-tablet regimens (STRs) for HIV-1 infection offer simplified treatment options. These newer antiretroviral therapy (ART) regimens improve adherence and reduce toxicity for patients.

Keywords:

HIV/AIDS adherence antiretrovirals dosage forms drug interactions

More Related Videos

Formation of Dispersible Taohong Siwu Tablets

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Related Experiment Videos

Last Updated: Feb 7, 2026

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Amplifying and Quantifying HIV-1 RNA in HIV Infected Individuals with Viral Loads Below the Limit of Detection by Standard Clinical Assays

Published on: September 26, 2011

Formation of Dispersible Taohong Siwu Tablets

Formation of Dispersible Taohong Siwu Tablets

Published on: February 3, 2023

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Humanized NOG Mice for Intravaginal HIV Exposure and Treatment of HIV Infection

Published on: January 31, 2020

Area of Science:

Pharmacology and Infectious Diseases
Antiretroviral Therapy Research
HIV-1 Treatment Strategies

Background:

Advancements in HIV-1 treatment have led to the development of new antiretroviral therapy (ART) regimens.
Single-tablet regimens (STRs) represent a significant simplification in daily HIV-1 medication management.
The landscape of HIV-1 treatment is rapidly evolving with new therapeutic options.

Purpose of the Study:

To review pharmacokinetics, safety, and drug-drug interactions (DDIs) of new single-tablet regimens (STRs) for HIV-1.
To evaluate the advantages and disadvantages of STRs approved since September 2016.
To provide a comprehensive overview of emerging STRs for HIV-1 management.

Main Methods:

Systematic literature search of PubMed (2004-2018) using keywords 'single tablet regimen' and 'HIV'.
Searches for individual STRs using generic names and specific additional terms.
Inclusion of published randomized controlled trials and observational studies, plus relevant conference abstracts.

Main Results:

Four new STRs have been approved, including the first dual ART regimen for virologically suppressed individuals.
One STR is a novel molecular entity; others are new combinations of existing agents.
These new STRs present distinct advantages and disadvantages impacting clinical practice.

Conclusions:

New STRs and pipeline agents continue to simplify ART regimens for HIV-1.
These simplified regimens are associated with increased medication adherence.
Minimizing treatment toxicities is a key benefit of newer STRs.